Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07USV
|
|||
| Former ID |
DNCL002100
|
|||
| Drug Name |
MM-302
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Phase 1 | [1] | |
| Company |
Merrimack Pharmaceuticals
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01304797) Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Whole-body organ-level and kidney micro-dosimetric evaluations of (64)Cu-loaded HER2/ErbB2-targeted liposomal doxorubicin ((64)Cu-MM-302) in rodents and primates. EJNMMI Res. 2015 Apr 14;5:24. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.